Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy

Phase 4

Withdrawn

• Conditions: Lymphoma; Osteoporosis
• Interventions: Radiation: Bone densitometry.

• Registration Number: NCT01841814
• Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Brief Summary

The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-04
• Primary Completion: 2013-04
• Study Completion: 2013-04
• Study First Submitted: 2013-04-22
• Study First Submitted QC: 2013-04-24
• Study First Posted: 2013-04-29
• Status Verified: 2016-12
• Last Update Submitted: 2016-12-02
• Last Update Posted: 2016-12-05

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Subjects aged 18 to 80 with lymphoma,
• Histological diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) of follicular or aggressive (large cell or other),
• Patients who have not yet started their chemotherapy or who have started for less than a month
• Patient has signed informed consent.

Exclusion Criteria

• Pathological fractures at the time of initial diagnosis of lymphoma,
• Compression of neurological epidural,
• Patients receiving treatment for osteoporosis (including bisphosphonates, selective modulators of estrogen receptor, calcitonin and parathyroid hormone Teriparatide).
• Discovery of osteoporosis or osteopenia fracture during the initial evaluation requiring the establishment of an osteoporosis treatment,
• Radiotherapy to the lumbar spine or hip studied,
• Location of bone lymphoma in the lumbar spine or hip studied,
• History of disorders affecting bone metabolism (prostate cancer with androgen, stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...)
• A person incapable of giving consent personally,
• Pregnant or breastfeeding women,
• Protected Person (under guardianship)
• Patient not affiliated with a social security system.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
lymphoma	Bone densitometry.	-

Primary Outcome Measures

Name	Time	Method
Measurement of bone mineral density (BMD).	Change from Baseline of bone mineral density at 12 months.	Patients will have a review of bone densitometry.

Trial Locations

Locations (1)

Gandhi DAMAJ; 🇫🇷 Amiens, Picardie, France